
How RSV manipulates the immune response in respiratory cells
TWINCORE researchers investigate gene activity in host cells

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.
This year's TWINCORE Symposium will take place on 3 - 4 September.

TWINCORE researchers investigate gene activity in host cells

Diverse Origins – One Goal

The 23rd doctoral thesis to receive an award at TWINCORE
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Vandenabeele L, Ayanwale A, Pietschmann T, Nilsson-Payant B
Dinkelborg K, Niehaus C, Bremer B, Wundes C, Tiede A, Petruch N, Deterding K, Kraft A, Hartleben B, Cornberg M, Wedemeyer H, Behrendt P, Maasoumy B
Berg K, Haid S, Vafadarnejad E, Carpentier A, Geffers R, Wiegmann B, Saliba A, Erhard F, Pietschmann T
Immunomodulatory drugs can have systemic side effects. This project is testing nanocarriers that deliver drugs specifically into myeloid immune cells in order to reduce side effects and increase the local effect.
The project investigates how HCMV is recognized by the immune system and which mechanisms the virus uses to camouflage itself. The aim is to understand the immune reactions and develop therapies for severely affected patients.
The project is developing methods to specifically transport antibiotics into cells such as alveolar macrophages, which are important in Mycobacterium tuberculosis infections. The aim is to overcome resistance and reduce side effects.
We develop high-throughput screening assays to identify antiviral molecules against RSV and SARS-CoV-2. We use compound libraries, investigate new mechanisms of action and strive for innovative therapies.

